<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0905210723
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rocuronium Bromide BOS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROCURONIUM BROMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        127.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gland Pharma Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gland Pharma Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M03AC09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rocuronium Bromide TBM is one of a group of drugs called muscle relaxants. Muscle relaxants are used during an operation as part of a general anaesthetic. When you have an operation, your muscles must be completely relaxed. This makes it easier for the surgeon to perform the operation.</p><p>Normally, your nerves send messages called impulses to your muscles. Rocuronium Bromide TBM acts by blocking these impulses so that your muscles relax. Because your breathing muscles also relax, you will need help to breathe (artificial ventilation) during and after your operation until you can breathe on your own again.</p><p>During the operation your anaesthetist will keep a check on the effect of the muscle relaxant, and if necessary, will give you some more. At the end of surgery, the effects of the drug are allowed to wear off and you will start breathing on your own. Sometimes the anaesthetist will give you another drug to help speed this up.</p><p>Rocuronium Bromide TBM can also be used in Intensive Care Units to keep your muscles relaxed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&bull; If you are allergic </strong>(hypersensitive) to the rocuronium, the bromide ion, or any of the other ingredients of this medicine (listed in section 6)</p><p><strong>&mdash;&gt; Tell your anaesthetist if this applies&nbsp; to you. Warnings and precautions</strong></p><p>Talk to your anaesthetist before you receive this medicine:</p><p>&bull; if you are allergic to muscle relaxants</p><p>&bull; if you have had kidney, heart, liver or gall bladder disease</p><p>&bull; if you have had diseases affecting nerves and muscles</p><p>&bull; if you have fluid retention (oedema).</p><p><strong>&mdash;&gt; Tell your anaesthetist if any of these applies to you.</strong></p><p>&bull; if you have a history of malignant hyperthermia (sudden fever with rapid heartbeat, rapid breathing and stiffness, pain and/or weakness in your muscles)</p><p><strong>Some conditions may influence the effects of Rocuronium Bromide TBM </strong></p><p><strong>&mdash; for example:</strong></p><p>&bull; low calcium levels in the blood</p><p>&bull; low potassium levels in the blood</p><p>&bull; high magnesium levels in the blood</p><p>&bull; low levels of protein in the blood</p><p>&bull; too much carbon dioxide in the blood</p><p>&bull; loss of too much water from the body, for example by being sick, diarrhoea or sweating</p><p>&bull; over-breathing leading to too little carbon dioxide in the blood (alkalosis) &bull; general ill-health &bull; burns</p><p>&bull; being very overweight (obesity)</p><p>&bull; very low body temperature (hypothermia).</p><p>If you have any of these conditions, your anaesthetist will take it into account when deciding the correct dose of Rocuronium Bromide TBM for you.</p><p><strong>Children and Elderly</strong></p><p>Rocuronium Bromide TBM can be used in children (newborns and adolescence) and elderly but your anaesthetist should first assess your medical history</p><p><strong>Other medicines and Rocuronium Bromide TBM</strong></p><p><strong>Tell your anaesthetist if you are taking other medicines </strong>or have recently taken them. This includes medicines or herbal products that you have bought without a prescription. Rocuronium Bromide TBM may affect other medicines or be affected by them.</p><p><strong>Medicines which increase the effect of Rocuronium Bromide TBM:</strong></p><p>&bull; certain antibiotics</p><p>&bull; certain medicines for heart disease or high blood pressure (water tablets, calcium channel blockers, beta-blockers and quinidine)</p><p>&bull; certain anti-inflammatory medicines (corticosteroids)</p><p>&bull; medicines for manic depressive illness (bipolar disorder)</p><p>&bull; magnesium salts</p><p>&bull; certain medicines used to treat malaria.</p><p><strong>Medicines which decrease the effect of Rocuronium Bromide TBM:</strong></p><p>&bull; certain medicines for epilepsy</p><p>&bull; calcium chloride and potassium chloride</p><p>&bull; certain protease inhibitors called gabexate and ulinastatin.</p><p>In addition, you may be given other medicines before or during surgery which can alter the effects of Rocuronium Bromide TBM. These include certain anaesthetics, other muscle relaxants, medicines such as phenytoin and medicines which reverse the effects of Rocuronium Bromide TBM. Rocuronium Bromide TBM may make certain anaesthetics work more quickly. Your anaesthetist will take this into account when deciding the correct dose of Rocuronium Bromide TBM for you.</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>Tell your anaesthetist if you are pregnant or might be pregnant, or if you are breast feeding.</strong></p><p>Your anaesthetist may still give you Rocuronium Bromide TBM, but you need to discuss it first. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your anaesthetist or other doctor for advice before taking this medicine. Rocuronium Bromide TBM may be given to you if you are having a Caesarean section.</p><p>Breastfeeding should be suspended 6 hours after use of this medicine.</p><p><strong>Driving and using machines</strong></p><p>Do not drive or use machines until advised it is safe to do so. Because Rocuronium Bromide TBM is given as part of a general anaesthetic, you may feel tired, weak or dizzy for some time afterwards. Your anaesthetist will be able to advise you on how long the effects are likely to last.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rocuronium Bromide TBM will be given to you by your anaesthetist. Rocuronium Bromide TBM is given intravenously (into a vein), either as single injections or as a continuous infusion (a drip).</p><p><strong>Dose</strong></p><p>Your anaesthetist will work out the dose of Rocuronium Bromide TBM you need based on:</p><p>&bull; the type of anaesthetic</p><p>&bull; the expected length of the operation</p><p>&bull; other drugs you are taking</p><p>&bull; your state of health.</p><p>The normal dose is 0.6 mg per kg body weight and the effect will last 30&ndash;40 minutes.</p><p><strong>If you are given more Rocuronium Bromide TBM than you need </strong></p><p>As your anaesthetist will be monitoring your condition carefully it is unlikely that you will be given too much Rocuronium Bromide TBM. However, if this happens, your anaesthetist will keep you breathing artificially (on a ventilator) until you can breathe on your own. You will be kept asleep while this takes place.</p><p>If you have any further questions on the use of this medicine, ask your anaesthetist or doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If these side effects occur while you are under anaesthetic, they will be seen and treated by your anaesthetist.</p><p><strong>Uncommon side effects</strong> (may affect up to 1 in 100 people)</p><p>&bull; the drug is too effective, or not effective enough</p><p>&bull; the drug works for longer than expected</p><p>&bull; lowering of blood pressure</p><p>&bull; increase in heart rate</p><p>&bull; pain near the site of injection.</p><p><strong>Very rare side effects </strong>(may affect up to 1 in 10,000 people)</p><p>&bull; allergic (hypersensitivity) reactions (such as difficulty in breathing, collapse of the circulation and shock)</p><p>&bull; wheezing of the chest</p><p>&bull; muscle weakness</p><p>&bull; swelling, a rash or redness of the skin.</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data)</p><p>&bull; severe allergic coronary blood vessels spasm (Kounis syndrome) resulting in chest pain (angina) or heart attack (myocardial infarction).</p><p><strong>If any of the side effects gets serious</strong></p><p>Or if you notice any side effects not listed in this leaflet:</p><p><strong>&mdash;&gt; Tell your anaesthetist or other docto</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The hospital will keep Rocuronium Bromide TBM according to the correct storage conditions and will ensure that it&#39;s in its expiry date.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active ingredient of this product is rocuronium bromide.</p><p>&bull; The other ingredients are sodium acetate trihydrate, sodium chloride, glacial acetic acid, sodium hydroxide, water for injection, nitrogen. Each millilitre (ml) of Rocuronium Bromide TBM contains 1.56 mg of sodium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rocuronium Bromide TBM is a clear, colourless to yellow or orange solution 
contains 10 mg of Rocuronium Bromide per mL. The product is packed as 10 
mg per mL rocuronium bromide in 5 mL USP Type I clear glass vial, stoppered 
with a 13 mm ready to sterilize Bromobutyl rubber stoppers and sealed with 13 
mm aluminium flip off seals.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tadawi Biomedical Company</p><p>Sudair Industrial Zone,</p><p>Sudair,</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                XXXX
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>روكيورونيوم برومايد تي بي إم</strong> هو واحد من مجموعة الأدوية المسماة مرخيات العضلات.</p><p dir="RTL">تسُتخدم مرخيات العضلات أثناء العملية كجزء من التخدير العام. عندما تخضع لعملية جراحية، يجب أن تكون عضلاتك مسترخية تماماً. وهذا مما يسهِّل على الجراح إجراء العملية.</p><p dir="RTL">عادة، ترسل أعصابك رسائل إلى العضلات تسُمى نبضات. يعمل <strong>روكيورونيوم برومايد تي بي إم </strong>على منع هذه النبضات بحيث تسترخي عضلاتك. ولأن عضلات التنفس تسترخي أيضاً، فأنت ستحتاج للمساعدة على التنفس) التنفس الاصطناعي( أثناء وبعد العملية حتى تتمكن من التنفس بنفسك مرة أخرى.</p><p dir="RTL">خلال العملية، سيراقب طبيب التخدير تأثير مرخيات العضلات، وسيعطيك المزيد إذا لزم الأمر. بنهاية الجراحة، يتم زوال تأثيرات الدواء وستبدأ في التنفس بنفسك. في بعض الأحيان يعطيك طبيب التخدير دواءً آخر يساعد على سرعة التنفس.&nbsp;</p><p dir="RTL">يمكن استخدام <strong>روكيورونيوم برومايد تي بي إم</strong> في وحدات العناية المركزة للحفاظ على عضلاتك مسترخية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا ينبغي أن تتلقى <strong>روكيورونيوم برومايد تي بي إم</strong>.</p><p dir="RTL">&bull;&nbsp; إذا كان لديك حساسية )حساسية شديدة( تجاه روكيورونيوم، برومايد أيون، أو أي من المكونات الأخرى لهذا الدواء )المذكورة في القسم 6).</p><p dir="RTL"><strong>&larr; أخبر طبيب التخدير الخاص بك إذا كان هذا ينطبق عليك. </strong></p><p dir="LTR"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المحاذير والاحتياطا ت </strong></p><p dir="RTL">تحدث إلى طبيب التخدير قبل تلقي هذا الدواء:&nbsp;</p><p dir="RTL">&bull;&nbsp; إذا كان لديك حساسية تجاه <strong>مرخيات العضلات</strong>.</p><p dir="RTL">&bull;&nbsp; إذا كنت قد عانيت من أمراض الكلى، القلب، الكبد أو المرارة.</p><p dir="RTL">&bull;&nbsp; إذا كنت قد عانيت من أمراض تؤثر على <strong>الأعصاب والعضلات</strong>.</p><p dir="RTL">&bull;&nbsp; إذا كان لديك <strong>احتباس للسوائل</strong>(وذمة).&nbsp;</p><p dir="LTR"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&larr; أخبر طبيب التخدير الخاص بك إذا كان أي من هذه ينطبق عليك.&nbsp; </strong></p><p dir="RTL">&bull;&nbsp; إذا كان لديك تاريخ مرضي في ارتفاع الحرارة الخبيث (حمى مفاجئة مع سرعة ضربات القلب، سرعة في التنفس وتصلب، ألم و/أو ضعف في عضلاتك).&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>قد تؤثر بعض الحالات على تأثير روكيورونيوم برومايد تي بي إم - على سبيل المثال:&nbsp; </strong></p><p dir="RTL">&bull;&nbsp; انخفاض مستويات الكالسيوم في الدم.&nbsp;</p><p dir="RTL">&bull;&nbsp; انخفاض مستويات البوتاسيوم في الدم.</p><p dir="RTL">&bull;&nbsp; ارتفاع مستويات المغنيسيوم في الدم.</p><p dir="RTL">&bull;&nbsp; انخفاض مستويات البروتين في الدم.</p><p dir="RTL">&bull;&nbsp; ارتفاع ثاني أكسيد الكربون في الدم.</p><p dir="RTL">&bull;&nbsp; فقدان الكثير من الماء من الجسم، على سبيل المثال بسبب مرض، إسهال أو تعرق.</p><p dir="RTL">إفراط في التنفس مما يؤدي لقلة كمية ثاني أكسيد الكربون في الدم )القلويدات(.&nbsp;</p><p dir="RTL">اعتلال الصحة العامة.&nbsp;</p><p dir="RTL">&bull;&nbsp; حروق.&nbsp;</p><p dir="RTL">&bull;&nbsp; زيادة وزن مفرطة (السمنة).</p><p dir="RTL">&bull;&nbsp; انخفاض شديد بدرجة حرارة الجسم (انخفاض حرارة الجسم).&nbsp;</p><p dir="RTL">إذا كان لديك أي من هذه الحالات، فإن طبيب التخدير الخاص بك سيأخذ ذلك بالاعتبار عند تحديد جرعتك الصحيحة من <strong>روكيورونيوم برومايد تي بي إم</strong>.&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>الأطفال وكبار السن </strong></p><p dir="RTL">يمكن استخدام <strong>روكيورونيوم برومايد تي بي إم </strong>لدى الأطفال )حديثي الولادة والمراهقين( وكبار السن ولكن على طبيب التخدير الخاص بك أن يقيمِّ أولاً تاريخك الطبي.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى و روكيورونيوم برومايد تي بي إ م </strong></p><p dir="RTL"><strong>أخبر طبيب التخدير إذا كنت تتناول أدوية أخرى</strong> أو قد تناولتها مؤخراً. ويشمل ذلك الأدوية أو المنتجات العشبية التي تشتريها بدون وصفة طبية. قد يؤثر <strong>روكيورونيوم برومايد تي بي إم </strong>على الأدوية الأخرى أو قد يتأثر بها.&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>الأدوية التي تزيد من تأثير روكيورونيوم برومايد تي بي إم: </strong></p><p dir="RTL">&bull;&nbsp; بعض <strong>المضادات الحيوية</strong>.</p><p dir="RTL">&bull;&nbsp; بعض أدوية <strong>أمراض القلب</strong> أو <strong>ارتفاع ضغط الدم</strong> (أقراص الماء، حاصرات قنوات الكالسيوم، حاصرات بيتا وكينيدين).&nbsp;</p><p dir="RTL">&bull;&nbsp; بعض الأدوية <strong>المضادة للالتهابات</strong> (الكورتيكوستيروي دا ت).</p><p dir="RTL">&bull;&nbsp; أدوية <strong>مرض الاكتئاب الهوسي</strong> (اضطراب ثنائي القطب).</p><p dir="RTL">&bull;&nbsp; <strong>أملاح المغنيسيوم</strong>.&nbsp;</p><p dir="RTL">&bull;&nbsp; بعض الأدوية المستخدمة لمعالجة <strong>الملاريا</strong>.&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>الأدوية التي تقلل من تأثير روكيورونيوم برومايد تي بي إم: </strong></p><p dir="RTL">&bull;&nbsp; بعض أدوية <strong>الصرع</strong>.</p><p dir="RTL"><strong>كالسيوم كلورايد</strong> و<strong>بوتاسيوم كلورايد</strong>.&nbsp;</p><p dir="RTL">بعض <strong>مثبطات البروتياز</strong> تسمى جابيكسات وأوليناستاتين.</p><p dir="RTL">إضافة إلى ذلك، قد تعُطى أدوية أخرى قبل أو أثناء الجراحة والتي يمكن أن تغير تأثيرات <strong>روكيورونيوم برومايد تي بي إم</strong>. وتشمل هذه بعض أدوية التخدير، مرخيات العضلات الأخرى، أدوية مثل فينيت و ين</p><p dir="RTL">وأدوية تعكس تأثيرات <strong>روكيورونيوم برومايد تي بي إم</strong>. قد يجعل <strong>روكيورونيوم برومايد تي بي إم </strong>بعض</p><p dir="RTL">المواد المخدرة تعمل بشكل أسرع. سيأخذ طبيب التخدير ذلك بعين الاعتبار عند تحديد جرعتك الصحيحة من <strong>روكيورونيوم برومايد تي بي إم</strong>.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL"><strong>أخبري طبيب التخدير إذا كنتِ حاملاً أو قد تكونين حاملاً، أو إذا كنتِ مرضعة. </strong></p><p dir="RTL">قد يستمر طبيب التخدير الخاص بكِّ بإعطائكِّ <strong>روكيورونيوم برومايد تي بي إم</strong>، ولكن عليك البحث معه أولاً. إذا كنتِّ حاملاً أو مرضعةً، تظنينَ بأنكِّ قد تكونينَ حاملاً أو تخططينَ لإنجاب طفلٍ، اطلبي مشورة طبيب التخدير أو طبيب آخر قبل تناول هذا الدواء. يمكن إعطاؤكِّ <strong>روكيورونيوم برومايد تي بي إم</strong> إذا كان لديك عملية قيصرية.&nbsp;</p><p dir="RTL">يجب إيقاف الرضاعة الطبيعية لمدة 6 ساعات من استخدام هذا الدواء.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">لا تقود أو تستخدم الآلات مالم ينُصح بذلك. نظرًا لأن <strong>روكيورونيوم برومايد تي بي إم</strong> يعُطى لك كجزء من مخدر عام، فقد تشعر بعد ذلك بالتعب، الضعف أو الدوار لبعض الوقت. سيكون طبيب التخدير الخاص بك قادراً على تقديم المشورة لك حول المدة المحتملة لاستمرار التأثيرات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيعطيك طبيب التخدير <strong>روكيورونيوم برومايد تي بي إم</strong>. ويعُطى <strong>روكيورونيوم برومايد تي بي إم</strong> عن طريق الوريد (داخل الوريد(، إما بحُقن مفردة أو بالتسريب المستمر (بالتنقيط).</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة </strong></p><p dir="RTL">سيعمد طبيب التخدير على تحديد جرعة <strong>روكيورونيوم برومايد تي بي إم</strong> التي تحتاجها بناءً على :</p><p dir="RTL">&bull;&nbsp; نوع المخدر.</p><p dir="RTL">&bull;&nbsp; المدة المتوقعة للعملية.</p><p dir="RTL">الأدوية الأخرى التي تتناولها.</p><p dir="RTL">حالتك الصحية.&nbsp;</p><p>&nbsp;</p><p dir="RTL">الجرعة الاعتيادية هي 6,0ملغ لكل كيلوغرام من وزن الجسم ويستمر التأثير من 30 إلى 40 دقيقة.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أعُطيتَ روكيورونيوم برومايد تي بي إم أكثر مما تحتا ج </strong></p><p dir="RTL">بما أن طبيب التخدير الخاص بك سيراقب حالتك بعناية، فمن غير المحتمل أن يتم إعطاؤك الكثير من <strong>روكيورونيوم برومايد تي بي إم</strong>. ومع ذلك، فإن حدث ذلك، سيبقيك طبيب التخدير على التنفس الاصطناعي (على جهاز التنفس الاصطناعي) حتى تتمكن من التنفس بنفسك. سوف تبقى نائماً أثناء حدوث ذلك.</p><p dir="RTL">إذا كان لديك أية أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيب التخدير أو طبيب آخر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء تأثيرات جانبية، وإن كانت لا تحدث لكل شخص. إذا حدثت لك هذه التأثيرات الجانبية أثناء التخدير، سوف تشُاهد وتعُالج من قبل طبيب التخدير .</p><p>&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية غير شائعة</strong> (قد تؤثر حتى في 1 من كل 100 شخص)</p><p dir="RTL">&bull; الدواء ف عال للغاية، أو غير ف عال بما فيه الكفاية.</p><p dir="RTL">&bull; يعمل الدواء لفترة أطول من المتوقع.</p><p dir="RTL">&bull; خفض ضغط الدم.</p><p dir="RTL">&bull; زيادة معدل ضربات القلب.</p><p dir="RTL">&bull; ألم بالقرب من مكان الحقن.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية نادرة جد اً</strong> (قد تؤثر حتى في 1 من كل 10000 شخص)</p><p dir="RTL">&bull; تفاعلات تحسسية (فرط حساسية)مثل صعوبة في التنفس، انهيار الدورة الدموية والصدمة.</p><p dir="RTL">&bull; صفير في الصدر.</p><p dir="RTL">&bull; ضعف العضلات.</p><p dir="RTL">&bull; تورُّم، طفح أو احمرار في الجلد.</p><p>&nbsp;</p><p dir="RTL"><strong>غير معروفة</strong>&nbsp;(لا يمكن تقدير تكرارها من البيانات المتاحة)</p><p dir="RTL">&bull;&nbsp;تشنج تحسسي شديد في أوعية تاجية دموية (متلازمة كونيس) يؤدي إلى ألم في الصدر (ذبحة صدرية) أو نوبة قلبية (احتشاء عضلة القلب).</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أصبحت أياًّ من التأثيرات الجانبية خطير ة </strong></p><p dir="RTL">أو إذا لاحظت أية تأثيرات جانبية غير مدرجة في هذه النشرة:&nbsp;</p><p dir="RTL"><strong>&larr; أخبر طبيب التخدير أو طبيب آخر.&nbsp; </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ستحتفظ المستشفى بدواء <strong>روكيورونيوم برومايد تي بي إم</strong> طبقاً لشروط التخزين الصحيحة وستضمن أنه ضمن تاريخ انتهاء صلاحيته.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;المادة الفعالة لهذا المنتج هي روكيورونيوم برومايد.&nbsp;</p><p dir="RTL">&bull;&nbsp;المكونات الأخرى هي تريهيدرات أسيتات الصوديوم، كلورايد الصوديوم، حمض الأسيتيك الجليدي ،هايدروكسي د الصوديوم، ماء للحقن، نيتروجين. يحتوي كل مليليتر )مل( من <strong>روكيورونيوم برومايد تي بي إم</strong> على 56,1 ملغ صوديوم.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>روكيورونيوم برومايد تي بي إم</strong> هو محلول شفاف، عديم اللون إلى أصفر أو برتقالي يحتوي على 10 ملغ روكيورونيوم برومايد في كل مل. والمنتج معبأ بمقدار 10 ملغ لكل مل من روكيورونيوم برومايد في قارورة زجاجية شفافة من النوع I وفق دستور الأدوية الأمريكي سعة 5 مل، مغلقة بسدادات جاهزة للتعقيم من مطاط بروموبوتيل بقطر 13 مم ومختومة بأختام ألمنيوم قطر 13 مم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة تداوي الحيوية الطبية</p><p dir="RTL">منطقة سدير الصناعية،&nbsp; سدير،</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            XXXX
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rocuronium Bromide TBM 
Rocuronium Bromide Injection, 10 mg/mL, 5 mL vial 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 mL vial contains 50 mg of rocuronium bromide. 
Excipient with known effect 
Each millilitre (ml) of Rocuronium Bromide TBM contains 1.56 mg of sodium. 
For the full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for Injection 
Clear, colourless to yellow or orange solution. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rocuronium Bromide TBM is indicated in adult and paediatric patients (from term neonates to adolescents [0 to &lt;18 years]) as an adjunct to general anaesthesia to facilitate tracheal intubation during routine sequence induction and to provide skeletal muscle relaxation during surgery. In adults Rocuronium Bromide TBM is also indicated to facilitate tracheal intubation during rapid sequence induction and as an adjunct in the intensive care unit (ICU) to facilitate intubation and mechanical ventilation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>Like other neuromuscular blocking agents, Rocuronium Bromide TBM should only be administered by, or under supervision of, experienced clinicians who are familiar with the action and use of these drugs.</p><p>As with other neuromuscular blocking agents, the dosage of rocuronium bromide should be individualised in each patient. The method of anaesthesia and the expected duration of surgery, the method of sedation and the expected duration of mechanical ventilation, the possible interaction with other drugs that are administered concomitantly, and the condition of the patient should be taken into account when determining the dose.</p><p>The use of an appropriate neuromuscular monitoring technique is recommended for the evaluation of neuromuscular block and recovery.</p><p>Inhalational anaesthetics do potentiate the neuromuscular blocking effects of rocuronium bromide. This potentiation however, becomes clinically relevant in the course of anaesthesia, when the volatile agents have reached the tissue concentrations required for this interaction. Consequently, adjustments with rocuronium bromide should be made by administering smaller maintenance doses at less frequent intervals or by using lower infusion rates of rocuronium bromide during long lasting procedures (longer than 1 hour) under inhalational anaesthesia (see section 4.5).</p><p>In adult patients the following dosage recommendations may serve as a general guideline for tracheal intubation and muscle relaxation for short to long lasting surgical procedures and for use in the intensive care unit. <em>Surgical Procedures </em><u>Tracheal intubation</u></p><p>The standard intubating dose during routine anaesthesia is 0.6 mg/kg rocuronium bromide, after which adequate intubation conditions are established within 60 seconds in nearly all patients. A dose of 1.0 mg/kg rocuronium bromide is recommended for facilitating tracheal intubation conditions during rapid sequence induction of anaesthesia, after which adequate intubation conditions are established within 60 seconds in nearly all patients. If a dose of 0.6 mg/kg rocuronium bromide is used for rapid sequence induction of anaesthesia, it is recommended to intubate the patient 90 seconds after administration of rocuronium bromide.</p><p>For use of rocuronium bromide during rapid sequence induction of anaesthesia in patients undergoing Caesarean section reference is made to section 4.6.</p><p>Maintenance dosing</p><p>The recommended maintenance dose is 0.15 mg/kg rocuronium bromide; in the case of longterm inhalational anaesthesia this should be reduced to 0.075-0.1 mg/kg rocuronium bromide. The maintenance doses should best be given when twitch height has recovered to 25% of control twitch height, or when 2 to 3 responses to train of four stimulation are present.</p><p>Continuous infusion</p><p>If rocuronium bromide is administered by continuous infusion, it is recommended to give a loading dose of 0.6 mg/kg rocuronium bromide and, when neuromuscular block starts to recover, to start administration by infusion. The infusion rate should be adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 to 2 responses to train of four stimulation. In adults under intravenous anaesthesia, the infusion rate required to maintain neuromuscular block at this level ranges from 0.3-0.6 mg/kg/h (300-600 micrograms/kg/h) and under inhalational anaesthesia the infusion rate ranges from 0.3-0.4 mg/kg/h. Continuous monitoring of neuromuscular block is essential since infusion rate requirements vary from patient to patient and with the anaesthetic method used.</p><p>Paediatric population</p><p>For neonates (0-27 days), infants (28 days-2 months), toddlers (3-23 months), children (2-11 years) and adolescents (12-17 years) the recommended intubation dose during routine anaesthesia and maintenance dose are similar to those in adults.</p><p>However, the duration of action of the single intubating dose will be longer in neonates and infants than in children (see section 5.1).</p><p>For continuous infusion in paediatrics, the infusion rates, with the exception of children (2-11 years), are the same as for adults. For children aged 2-11 years higher infusion rates might be necessary.</p><p>Thus, for children (2-11 years) the same initial infusion rates as for adults are recommended and then this should be adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 or 2 responses to train of four stimulation during the procedure.</p><p>The experience with rocuronium bromide in rapid sequence induction in paediatric patients is limited. Rocuronium bromide is therefore not recommended for facilitating tracheal intubation conditions during rapid sequence induction in paediatric patients.</p><p>Geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure</p><p>The standard intubation dose for geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure during routine anaesthesia is 0.6 mg/kg rocuronium bromide. A dose of 0.6 mg/kg should be considered for rapid sequence induction of anaesthesia in patients in which a prolonged duration of action is expected. Regardless of the anaesthetic technique used, the recommended maintenance dose for these patients is 0.075-0.1 mg/kg rocuronium bromide, and the recommended infusion rate is 0.3-0.4 mg/kg/h (see Continuous infusion) (see also section 4.4).</p><p>Overweight and obese patients</p><p>When used in overweight or obese patients (defined as patients with a body weight of 30% or more above ideal body weight) doses should be reduced taking into account ideal body weight.</p><p>&nbsp;</p><p><em>Intensive Care Procedures </em></p><p>Tracheal intubation</p><p>For tracheal intubation, the same doses should be used as described above under surgical procedures.</p><p>Maintenance dosing</p><p>The use of an initial loading dose of 0.6 mg/kg rocuronium bromide is recommended, followed by a continuous infusion as soon as twitch height recovers to 10% or upon reappearance of 1 to 2 twitches to train of four stimulation. Dosage should always be titrated to effect in the individual patient. The recommended initial infusion rate for the maintenance of a neuromuscular block of 80-90% (1 to 2 twitches to TOF stimulation) in adult patients is 0.3-0.6 mg/kg/h during the first hour of administration, which will need to be decreased during the following 6-12 hours, according to the individual response. Thereafter, individual dose requirements remain relatively constant.</p><p>A large between patient variability in hourly infusion rates has been found in controlled clinical studies, with mean hourly infusion rates ranging from 0.2-0.5 mg/kg/h depending on nature and extent of organ failure(s), concomitant medication and individual patient characteristics. To provide optimal individual patient control, monitoring of neuromuscular transmission is strongly recommended. Administration up to 7 days has been investigated.</p><p>Special populations</p><p>Rocuronium Bromide TBM is not recommended for the facilitation of mechanical ventilation in the intensive care in paediatric and geriatric patients due to a lack of data on safety and efficacy.</p><p>Method of administration</p><p>Rocuronium Bromide TBM is administered intravenously either as a bolus injection or as a continuous infusion (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to rocuronium bromide or to the bromide ion or any of the excipients. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since rocuronium bromide causes paralysis of the respiratory muscles, ventilatory support is mandatory for patients treated with this drug until adequate spontaneous respiration is restored. As with all neuromuscular blocking agents, it is important to anticipate intubation difficulties, particularly when used as part of a rapid sequence induction technique.</p><p>As with other neuromuscular blocking agents, residual neuromuscular blockade has been reported for rocuronium bromide. In order to prevent complications resulting from residual neuromuscular blockade, it is recommended to extubate only after the patient has recovered sufficiently from neuromuscular block. Geriatric patients (65 years or older) may be at increased risk for residual neuromuscular block. Other factors which could cause residual neuromuscular blockade after extubation in the post-operative phase (such as drug interactions or patient condition) should also be considered. If not used as part of standard clinical practice, the use of a reversal agent (such as sugammadex or acetylcholinesterase inhibitors) should be considered, especially in those cases where residual neuromuscular blockade is more likely to occur.</p><p>High rates of cross-sensitivity between neuromuscular blocking agents have been reported. Therefore, where possible, before administering rocuronium bromide, hypersensitivity to other neuromuscular blocking agents should be excluded. Rocuronium bromide should only be used when absolutely essential in susceptible patients. Patients who experience a hypersensitivity reaction under general anaesthesia should be tested subsequently for hypersensitivity to other neuromuscular blockers.</p><p>Rocuronium may increase the heart rate.</p><p>In general, following long term use of neuromuscular blocking agents in the ICU, prolonged paralysis and/or skeletal muscle weakness has been noted. In order to help preclude possible prolongation of neuromuscular block and/or overdosage it is strongly recommended that neuromuscular transmission is monitored throughout the use of neuromuscular blocking agents. In addition, patients should receive adequate analgesia and sedation. Furthermore, neuromuscular blocking agents should be titrated to effect in the individual patients by or under supervision of experienced clinicians who are familiar with their actions and with appropriate neuromuscular monitoring techniques.</p><p>Myopathy after long term administration of other non-depolarising neuromuscular blocking agents in the ICU in combination with corticosteroid therapy has been reported regularly. Therefore, for patients receiving both neuromuscular blocking agents and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible.</p><p>If suxamethonium is used for intubation, the administration of rocuronium bromide should be delayed until the patient has clinically recovered from the neuromuscular block induced by suxamethonium.</p><p>Because rocuronium bromide is always used with other drugs and because of the risk of malignant hyperthermia during anaesthesia, even in the absence of known triggering factors, physicians should be aware of the early symptoms, confirmatory diagnosis and treatment of malignant hyperthermia prior to the start of anaesthesia. Animal studies have shown that rocuronium bromide is not a triggering factor for malignant hyperthermia. Rare cases of malignant hyperthermia with rocuronium bromide have been observed through post-marketing surveillance; however, the causal association has not been proven.</p><p><em>The following conditions may influence the pharmacokinetics and/or pharmacodynamics of rocuronium bromide: </em></p><p>Hepatic and/or biliary tract disease and renal failure</p><p>Because rocuronium is excreted in urine and bile, it should be used with caution in patients with clinically significant hepatic and/or biliary diseases and/or renal failure. In these patient groups prolongation of action has been observed with doses of 0.6 mg/kg rocuronium bromide.</p><p>Prolonged circulation time</p><p>Conditions associated with prolonged circulation time such as cardiovascular disease, old age and oedematous state resulting in an increased volume of distribution, may contribute to a slower onset of action. The duration of action may also be prolonged due to a reduced plasma clearance.</p><p>Neuromuscular disease</p><p>Like other neuromuscular blocking agents, rocuronium bromide should be used with extreme caution in patients with a neuromuscular disease or after poliomyelitis since the response to neuromuscular blocking agents may be considerably altered in these cases. The magnitude and direction of this alteration may vary widely. In patients with myasthenia gravis or with the myasthenic (Eaton-Lambert) syndrome, small doses of rocuronium bromide may have profound effects and rocuronium bromide should be titrated to the response.</p><p>Hypothermia</p><p>In surgery under hypothermic conditions, the neuromuscular blocking effect of rocuronium bromide is increased and the duration prolonged.</p><p>Obesity</p><p>Like other neuromuscular blocking agents, rocuronium bromide may exhibit a prolonged duration and a prolonged spontaneous recovery in obese patients when the administered doses are calculated on actual body weight.</p><p>&nbsp;</p><p>&nbsp;</p><p>Burns</p><p>Patients with burns are known to develop resistance to non-depolarising neuromuscular blocking agents. It is recommended that the dose is titrated to response.</p><p>Conditions which may increase the effects of rocuronium bromide</p><p>Hypokalaemia (e.g. after severe vomiting, diarrhoea and diuretic therapy), hypermagnesaemia, hypocalcaemia (after massive transfusions), hypoproteinaemia, dehydration, acidosis, hypercapnia, cachexia.</p><p>Severe electrolyte disturbances, altered blood pH, or dehydration should therefore be corrected when possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following drugs have been shown to influence the magnitude and/or duration of action of non-depolarising neuromuscular blocking agents.</p><p><u>Effect of other drugs on rocuronium bromide</u> <em>Increased effect: </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Halogenated volatile anaesthetics potentiate the neuromuscular block of rocuronium bromide. The effect only becomes apparent with maintenance dosing (see section 4.2). Reversal of the block with acetylcholinesterase inhibitors could also be inhibited.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After intubation with suxamethonium.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-term concomitant use of corticosteroids and rocuronium bromide in the ICU may result in prolonged duration of neuromuscular block or myopathy (see section 4.4 and 4.8).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other drugs:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics: aminoglycoside, lincosamide and polypeptide antibiotics, acylamino-penicillin antibiotics.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diuretics, quinidine and its isomer quinine, magnesium salts, calcium channel blocking agents, lithium salts, local anaesthetics (lidocaine i.v, bupivacaine epidural) and acute administration of phenytoin or &szlig;-blocking agents.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurarisation has been reported after post-operative administration of: aminoglycoside, lincosamide, polypeptide and acylamino-penicillin antibiotics, quinidine, quinine and magnesium salts (see section 4.4).</p><p><em>Decreased effect: </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior chronic administration of phenytoin or carbamazepine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calcium chloride, potassium chloride.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protease inhibitors (gabexate, ulinastatin). <em>Variable effect: </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administration of other non-depolarising neuromuscular blocking agents in combination with rocuronium bromide may produce attenuation or potentiation of the neuromuscular block, depending on the order of administration and the neuromuscular blocking agent used.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suxamethonium given after the administration of rocuronium bromide may produce potentiation or attenuation of the neuromuscular blocking effect of rocuronium bromide.</p><p>Effect of rocuronium bromide on other drugs</p><p>Rocuronium bromide combined with lidocaine may result in a quicker onset of action of lidocaine.</p><p>Paediatric population</p><p>No formal interaction studies have been performed. The above mentioned interactions for adults and their special warnings and precautions for use (see section 4.4) should be taken into account for paediatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>For rocuronium bromide, no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Caution should be exercised when prescribing rocuronium bromide to pregnant women.</p><p>Caesarean section</p><p>In patients undergoing Caesarean section, rocuronium bromide can be used as part of a rapid sequence induction technique, provided no intubation difficulties are anticipated and a sufficient dose of anaesthetic agent is administered or following suxamethonium facilitated intubation. However, rocuronium bromide, administered in doses of 0.6 mg/kg may not produce adequate conditions for intubation until 90 seconds after administration. This dose has been shown to be safe in parturient undergoing Caesarean section. Rocuronium bromide does not affect Apgar score, foetal muscle tone or cardiorespiratory adaptation. From umbilical cord blood sampling it is apparent that only limited placental transfer of rocuronium bromide occurs which does not lead to the observation of clinical adverse effects in the newborn.</p><p>Note 1: doses of 1.0 mg/kg have been investigated during rapid sequence induction of anaesthesia, but not in Caesarean section patients. Therefore, only a dose of 0.6 mg/kg is recommended in this patient group.</p><p>Note 2: Reversal of neuromuscular block induced by neuromuscular blocking agents may be inhibited or unsatisfactory in patients receiving magnesium salts for toxaemia of pregnancy because magnesium salts enhance neuromuscular blockade. Therefore, in these patients the dosage of rocuronium bromide should be reduced and be titrated to twitch response.</p><p>Breast-feeding</p><p>It is unknown whether rocuronium bromide is excreted in human breast milk. Animal studies have shown insignificant levels of rocuronium bromide in breast milk.</p><p>Insignificant levels of rocuronium bromide were found in the milk of lactating rats. There are no human data on the use of rocuronium bromide during lactation. Rocuronium bromide should be given to lactating women only when the attending physician decides that the benefits outweigh the risks. After the administration of a single dose, it is recommended to abstain from next breastfeeding for five elimination half-lives of rocuronium, i.e. for about 6 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since Rocuronium Bromide TBM is used as an adjunct to general anaesthesia, the usual precautionary measures after a general anaesthesia should be taken for ambulatory patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Summary of the safety profile </em></p><p>The most commonly occurring adverse drug reactions include injection site pain/reaction, changes in vital signs and prolonged neuromuscular block. The most frequently reported serious adverse drug reactions during post-marketing surveillance is &#39;anaphylactic and anaphylactoid reactions&#39; and associated symptoms. See also the explanations below the table.</p><p>&nbsp;</p><p><em>Tabulated list of adverse reactions</em></p><table border="0" cellspacing="0" cellpadding="0" style="width:571px"><tbody><tr><td rowspan="2"><p><strong>MedDRA SOC </strong></p></td><td style="vertical-align:top"><p><strong>Preferred Term<sup>1</sup> </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Uncommon/Rare<sup>2</sup> </strong></p><p><strong>(&lt;1/100&nbsp; &ge;1/10000) </strong></p></td><td><p><strong>Very Rare (&lt;1/10000) </strong></p></td><td><p><strong>Not known </strong></p></td></tr><tr><td rowspan="3"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactoid reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>MedDRA SOC </strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Preferred Term<sup>1</sup> </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Uncommon/Rare<sup>2</sup> </strong></p><p><strong>(&lt;1/100&nbsp; &ge;1/10000) </strong></p></td><td><p><strong>Very Rare (&lt;1/10000) </strong></p></td><td><p><strong>Not known </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic shock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactoid shock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorder</p></td><td><p>&nbsp;</p></td><td><p>Flaccid paralysis</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Cardiac disorders</p></td><td><p>Tachycardia</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Kounis syndrome</p></td></tr><tr><td rowspan="2"><p>Vascular disorders</p></td><td><p>Hypotension</p></td><td style="vertical-align:top"><p>Circulatory collapse and shock</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>&nbsp;</p></td><td><p>Bronchospasm</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="4"><p>Skin and subcutaneous tissue disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioneurotic oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erythematous rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscular weakness<sup>3</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Steroid myopathy<sup>3</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Drug ineffective</p></td><td style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Drug effect/therapeutic response decreased</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Drug effect/therapeutic response increased</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection site pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection site reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Prolonged neuromuscular block</p></td><td style="vertical-align:top"><p>Airway complication of anaesthesia</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Delayed recovery from anaesthesia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>MedDRA version 8.1</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>1 &nbsp;Frequencies are estimates derived from post-marketing surveillance reports and data from the general literature. 2 &nbsp;Post-marketing surveillance data cannot give precise incidence figures. For that reason, the reporting frequency was divided over two rather than five categories.</p><p>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;after long-term use in the ICU.</p></td></tr></tbody></table><p>&nbsp;</p><p>Anaphylaxis</p><p>Although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. Anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse &ndash; shock), and cutaneous changes (e.g. angioedema, urticaria). These reactions have, in some cases, been fatal. Due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.</p><p>Since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematous reaction at the site of injection and/or generalised histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these drugs.</p><p>In clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3-0.9 mg/kg rocuronium bromide.</p><p>Prolonged neuromuscular block</p><p>The most frequent adverse reaction to non-depolarising blocking agents as a class consists of an extension of the drug&#39;s pharmacological action beyond the time period needed. This may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.</p><p>Myopathy</p><p>Myopathy has been reported after the use of various neuromuscular blocking agents in the ICU in combination with corticosteroids (see section 4.4).</p><p>Local injection site reactions</p><p>During rapid sequence induction of anaesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. In clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anaesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anaesthesia with fentanyl and thiopental.</p><p><u>Paediatric population</u>:</p><p>A meta-analysis of 11 clinical studies in paediatric patients (n=704) with rocuronium bromide (up to 1 mg/kg) showed that tachycardia was identified as adverse drug reaction with a frequency of 1.4%.</p><p><strong>To report any side effect(s): </strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the competent authority in Saudi Arabia as per details below:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>Saudi Arabia</u> </strong></p><p>&nbsp;</p><p>The National Pharmacovigilance Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>Other GCC States:</u> </strong></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority. </em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdosage and prolonged neuromuscular block, the patient should continue to receive ventilator support and sedation. There are two options for the reversal of neuromuscular block:</p><p>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In adults, sugammadex can be used for reversal of intense (profound) and deep block. The dose of sugammadex to be administered depends on the level of neuromuscular block.</p><p>(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An acetylcholinesterase inhibitor (e.g. neostigmine, edrophonium, pyridostigmine) or sugammadex can be used once spontaneous recovery starts and should be administered in adequate doses.&nbsp;</p><p>When administration of an acetylcholinesterase inhibiting agent fails to reverse the neuromuscular effects of rocuronium bromide, ventilation must be continued until spontaneous breathing is restored. Repeated dosage of an acetylcholinesterase inhibitor can be dangerous. In animal studies, severe depression of cardiovascular function, ultimately leading to cardiac collapse did not occur until a cumulative dose of 750 x ED<sub>90</sub> (135 mg/kg rocuronium bromide) was administered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Muscle relaxants, peripherally acting agents, ATC code: M03AC09.</p><p>Mechanism of action</p><p>Rocuronium bromide is a fast onset, intermediate acting non-depolarising neuromuscular blocking agent, possessing all of the characteristic pharmacological actions of this class of drugs (curariform). It acts by competing for nicotinic cholinoceptors at the motor end-plate. This action is antagonised by acetylcholinesterase inhibitors such as neostigmine, edrophonium and pyridostigmine.</p><p>Pharmacodynamics</p><p>The ED90 (dose required to produce 90% depression of the twitch response of the thumb to stimulation of the ulnar nerve) during intravenous anaesthesia is approximately 0.3 mg/kg rocuronium bromide. The ED95 in infants is lower than in adults and children (0.25, 0.35 and 0.40 mg/kg respectively).</p><p>The clinical duration (the duration until spontaneous recovery to 25% of control twitch height) with 0.6 mg/kg rocuronium bromide is 30&ndash;40 minutes. The total duration (time until spontaneous recovery to 90% of control twitch height) is 50 minutes. The mean time of spontaneous recovery of twitch response from 25 to 75% (recovery index) after a bolus dose of 0.6 mg/kg rocuronium bromide is 14 minutes. With lower dosages of 0.3-0.45 mg/kg rocuronium bromide (1 -1&frac12; x ED90), onset of action is slower and duration of action is shorter. With high doses of 2 mg/kg, clinical duration is 110 minutes.</p><p>Intubation during routine anaesthesia</p><p>Within 60 seconds following intravenous administration of a dose of 0.6 mg/kg rocuronium bromide (2 x ED<sub>90</sub> under intravenous anaesthesia), adequate intubation conditions can be achieved in nearly all patients of which in 80% intubation conditions are rated excellent. General muscle paralysis adequate for any type of procedure is established within 2 minutes. After administration of 0.45 mg/kg rocuronium bromide, acceptable intubation conditions are present after 90 seconds.</p><p>Rapid Sequence Induction</p><p>During rapid sequence induction of anaesthesia under propofol or fentanyl/thiopental anaesthesia, adequate intubation conditions are achieved within 60 seconds in 93% and 96% of the patients respectively, following a dose of 1.0 mg/kg rocuronium bromide. Of these, 70% are rated excellent. The clinical duration with this dose approaches 1 hour, at which time the neuromuscular block can be safely reversed. Following a dose of 0.6 mg/kg rocuronium bromide, adequate intubation conditions are achieved within 60 seconds in 81% and 75% of the patients during a rapid sequence induction technique with propofol or fentanyl/thiopental, respectively.</p><p>&nbsp;</p><p>&nbsp;</p><p>Paediatric population</p><p>Mean onset time in infants, toddlers and children at an intubation dose of 0.6 mg/kg is slightly shorter than in adults. Comparison within paediatric age groups showed that the mean onset time in neonates and adolescents (1.0 min.) is slightly longer than in infants, toddlers and children (0.4, 0.6 and 0.8 min., respectively). The duration of relaxation and the time to recovery tend to be shorter in children compared to infants and adults. Comparing within paediatric age groups demonstrated that mean time to reappearance of T3 was prolonged in neonates and infants (56.7 and 60.7 min, respectively) when compared to toddlers, children and adolescents (45.4, 37.6 and 42.9 min., respectively).</p><p>Mean (SD) time to onset and clinical duration following 0.6 mg/kg rocuronium initial intubating dose* during sevoflurane/nitrous oxide and isoflurane/nitrous oxide (maintenance) anaesthesia (Paediatric patients) PP group</p><table border="0" cellspacing="0" cellpadding="0" style="width:556px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Time to maximum block** </strong></p><p><strong>(min) </strong></p></td><td style="vertical-align:top"><p><strong>Time to reappearance of T<sub>3</sub>** </strong></p><p><strong>(min) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Neonates (0-27 days) n=10</p></td><td style="vertical-align:top"><p>0.98 (0.62)</p></td><td style="vertical-align:top"><p>56.69 (37.04) n=9</p></td></tr><tr><td style="vertical-align:top"><p>Infants (28 days-2 months) n=11</p></td><td style="vertical-align:top"><p>0.44 (0.19) n=10</p></td><td style="vertical-align:top"><p>60.71 (16.52)</p></td></tr><tr><td style="vertical-align:top"><p>Toddlers (3 months-23 months) n=28</p></td><td style="vertical-align:top"><p>0.59 (0.27)</p></td><td style="vertical-align:top"><p>45.46 (12.94) n=27</p></td></tr><tr><td style="vertical-align:top"><p>Children (2-11 years) n=34</p></td><td style="vertical-align:top"><p>0.84 (0.29)</p></td><td style="vertical-align:top"><p>37.58 (11.82)</p></td></tr><tr><td style="vertical-align:top"><p>Adolescents (12-17 years) n=31</p></td><td style="vertical-align:top"><p>0.98 (0.38)</p></td><td style="vertical-align:top"><p>42.90 (15.83) n=30</p></td></tr></tbody></table><p>* Dose of rocuronium administered within 5 seconds.</p><p>** Calculated from the end of administration of the rocuronium intubating dose</p><p>Geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure</p><p>The duration of action of maintenance doses of 0.15 mg/kg rocuronium bromide might be somewhat longer under enflurane and isoflurane anaesthesia in geriatric patients and in patients with hepatic and/or renal disease (approximately 20 minutes) than in patients without impairment of excretory organ functions under intravenous anaesthesia (approximately 13 minutes) (see section 4.2). No accumulation of effect (progressive increase in duration of action) with repetitive maintenance dosing at the recommended level has been observed.</p><p>Intensive Care Unit</p><p>Following continuous infusion in the Intensive Care Unit, the time to recovery of the train of four ratio to 0.7 depends on the level of block at the end of the infusion. After a continuous infusion for 20 hours or more the median (range) time between return of T2 to train of four stimulation and recovery of the train of four ratio to 0.7 approximates 1.5 (1-5) hours in patients without multiple organ failure and 4 (1-25) hours in patients with multiple organ failure.</p><p>Cardiovascular surgery</p><p>In patients scheduled for cardiovascular surgery the most common cardiovascular changes during the onset of maximum block following 0.6-0.9 mg/kg rocuronium bromide are a slight and clinically insignificant increase in heart rate up to 9% and an increase in mean arterial blood pressure up to 16% from the control values.</p><p>Reversal of muscle relaxation</p><p>Administration of acetylcholinesterase inhibitors, (neostigmine, pyridostigmine or edrophonium) at reappearance of T2 or at the first signs of clinical recovery, antagonises the action of rocuronium bromide.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After intravenous administration of a single bolus dose of rocuronium bromide the plasma concentration time course runs in three exponential phases. In normal adults, the mean (95% CI) elimination half-life is 73 (66-80) minutes, the (apparent) volume of distribution at steady state conditions is 203 (193-214) ml/kg and plasma clearance is 3.7 (3.5-3.9) ml/kg/min. Rocuronium is excreted in urine and bile. Excretion in urine approaches 40% within 12-24 hours. After injection of a radiolabeled dose of rocuronium bromide, excretion of the radiolabel is on average 47% in urine and 43% in faeces after 9 days. Approximately 50% is recovered as the parent compound. No metabolites are detected in plasma.</p><p>Paediatric population</p><p>Pharmacokinetics of rocuronium bromide in paediatric patients (n=146) with ages ranging from 0 to 17 years were evaluated using a population analysis of the pooled pharmacokinetic datasets from two clinical trials under sevoflurane (induction) and isoflurane/nitrous oxide (maintenance) anesthesia. All pharmacokinetic parameters were found to be linearly proportional to body weight illustrated by a similar clearance (l.hr<sup>-1</sup>.kg<sup>-1</sup>). The volume of distribution (l.kg-1) and elimination half-life (h) decrease with age (years). The pharmacokinetic parameters of typical paediatrics within each age group are summarized below:</p><p>Estimated PK parameters (mean [SD]) of rocuronium bromide in typical paediatric during sevoflurane and nitrous oxide (induction) and isoflurane/nitrious oxide (maintenance anaesthesia)</p><table border="0" cellspacing="0" cellpadding="0" style="width:571px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>PK Parameters</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Patient Age Range </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Term newborn </strong></p><p><strong>infants </strong></p><p><strong>(0-27 days) </strong></p></td><td style="vertical-align:top"><p><strong>Infants </strong></p><p><strong>(28 days to 2 months) </strong></p></td><td style="vertical-align:top"><p><strong>Toddlers </strong></p><p><strong>(3-23 months) </strong></p></td><td style="vertical-align:top"><p><strong>Children (2-11 years) </strong></p></td><td style="vertical-align:top"><p><strong>Adolescents (12-17 years) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Cl (L/Kg/hr)</p></td><td style="vertical-align:top"><p>0.31 (0.07)</p></td><td style="vertical-align:top"><p>0.30 (0.08)</p></td><td style="vertical-align:top"><p>0.33 (0.10)</p></td><td style="vertical-align:top"><p>0.35 (0.09)</p></td><td style="vertical-align:top"><p>0.29 (0.14)</p></td></tr><tr><td style="vertical-align:top"><p>Volume of&nbsp; distribution (L/Kg)</p></td><td style="vertical-align:top"><p>0.42 (0.06)</p></td><td style="vertical-align:top"><p>0.31 (0.03)</p></td><td style="vertical-align:top"><p>0.23 (0.03)</p></td><td style="vertical-align:top"><p>0.18 (0.02)</p></td><td style="vertical-align:top"><p>0.18 (0.01)</p></td></tr><tr><td style="vertical-align:top"><p>T1/2 &beta; (hr)</p></td><td style="vertical-align:top"><p>1.1 (0.2)</p></td><td style="vertical-align:top"><p>0.9 (0.3)</p></td><td style="vertical-align:top"><p>0.8 (0.2)</p></td><td style="vertical-align:top"><p>0.7 (0.2)</p></td><td style="vertical-align:top"><p>0.8 (0.3)</p></td></tr></tbody></table><p>Geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure</p><p>In controlled studies the plasma clearance in geriatric patients and in patients with renal dysfunction was reduced, in most studies however without reaching the level of statistical significance. In patients with hepatic disease, the mean elimination half-life is prolonged by 30 minutes and the mean plasma clearance is reduced by 1 ml/kg/min (see section 4.2).</p><p>Intensive Care unit</p><p>When administered as a continuous infusion to facilitate mechanical ventilation for 20 hours or more, the mean elimination half-life and the mean (apparent) volume of distribution at steady state are increased. A large between patient variability is found in controlled clinical studies, related to nature and extent of (multiple) organ failure and individual patient characteristics. In patients with multiple organ failure a mean (&plusmn; SD) elimination half-life of 21.5 (&plusmn; 3.3) hours, a (apparent) volume of distribution at steady state of 1.5 (&plusmn; 0.8) l/kg and a plasma clearance of 2.1 (&plusmn; 0.8) ml/kg/min were found (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.</p><p>There is no proper animal model to mimic the usually extremely complex clinical situation of the ICU patient. Therefore the safety of rocuronium bromide when used to facilitate mechanical ventilation in the Intensive Care Unit is mainly based on results obtained in clinical studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium acetate trihydrate</p><p>Sodium chloride</p><p>Glacial acetic acid</p><p>Sodium hydroxide</p><p>Water for injection Nitrogen</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Physical incompatibility has been documented for Rocuronium bromide when added to solutions containing the following drugs: amphotericin, amoxicillin, azathioprine, cefazolin, cloxacillin, dexamethasone, diazepam, enoximone, erythromycin, famotidine, furosemide, hydrocortisone sodium succinate, insulin, intralipid, methohexital, methylprednisolone, prednisolone sodium succinate, thiopental, trimethoprim and vancomycin.</p><p>Rocuronium bromide must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>If rocuronium bromide is administered via the same infusion line that is also used for other drugs, it is important that this infusion line is adequately flushed (e.g. with 0.9% NaCl) between administration of rocuronium bromide and drugs for which incompatibility with Rocuronium bromide has been demonstrated or for which compatibility with Rocuronium bromide has not</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months. 
After dilution with infusion fluids (see section 6.6), chemical and physical in-use stability has been demonstrated for 72 hours at 30°C. From a microbiological point of view, the diluted product should be used immediately or should be stored under refrigeration (2-8°C) and administered within 24 hours. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>between 2&deg;C-8&deg;C. Do not freeze.Rocuronium Bromide TBM is a clear, colourless to yellow or orange solution contains 10 mg of Rocuronium Bromide per mL. The product is packed as 10 mg rocuronium per mL rocuronium bromide in 5 mL USP Type I clear glass Vial, stoppered with a 13 mm ready to sterilize Bromobutyl rubber stoppers and sealed with 13 mm aluminium flip off seals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rocuronium Bromide TBM is a clear, colourless to yellow or orange solution contains 10 mg of Rocuronium Bromide per mL. The product is packed as 10 mg rocuronium per mL rocuronium bromide in 5 mL USP Type I clear glass Vial, stoppered with a 13 mm ready to sterilize Bromobutyl rubber stoppers and sealed with 13 mm aluminium flip off seals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rocuronium bromide is compatible upto 5 mg/mL for 24 hours at room temperature in solution with sterile water for injection, 0.9% NaCl solution, 5% glucose in water, 5% glucose in saline, and Lactated Ringers.</p><p>Infusion solutions should be used within 24 hours of mixing. Unused portions of infusion solutions should be discarded.</p><p>Parenteral drug products should be inspected visually for particulate matter and clarity prior to administration whenever solution and container permit. Do not use solution if particulate matter is present.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical - KSA,
Riyadh, Sudair Industrial Area,
Zone A, Road 11, Factory107,
Saudi Arabia 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XXXX
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>